李 欣學

Medicine & Life Sciences

1. Hematopoietic Stem Cell Transplantation 64%
2. Multiple Myeloma 37%
3. Registries 34%
4. Stem Cell Transplantation 34%
5. T-Cell Lymphoma 29%
6. Transplants 25%
7. Precursor Cell Lymphoblastic Leukemia-Lymphoma 25%
8. Drug Therapy 24%
9. AIC246 24%
10. Inotuzumab Ozogamicin 23%
11. Dexamethasone 23%
12. Survival 22%
13. daratumumab 21%
14. carfilzomib 20%
15. Hepatic Veno-Occlusive Disease 19%
16. Incidence 19%
17. Bone Marrow 19%
18. Primary Effusion Lymphoma 19%
19. Databases 18%
20. GATA2 Deficiency 17%
21. Thrombotic Thrombocytopenic Purpura 17%
22. T-Lymphocytes 16%
23. Human Herpesvirus 8 16%
24. Transplantation 16%
25. Bortezomib 15%
26. Thymoma 15%
27. Aplastic Anaemia 15%
28. Lymphoproliferative Disorders 15%
29. Hematologic Diseases 14%
30. Second Primary Neoplasms 14%
31. Organ Transplantation 13%
32. Cytomegalovirus 12%
33. Hematopoietic Stem Cells 12%
34. Serine 12%
35. Therapeutics 12%
36. Lymphoma 12%
37. Population 11%
38. Cost-Benefit Analysis 11%
39. B-Lymphocytes 10%
40. Young Adult 10%
41. Pneumonia 10%
42. Comorbidity 10%